Ellesmere Port

Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight. This phase 3 clinical trial compares weekly injections of NNC0487-0111 against placebo injections, both given under the skin. Participants also follow a reduced-calorie diet and increased physical activity as part of the study. Participants receive subcutaneous injections once a week of either NNC0487-0111 or a placebo. The study uses a randomized, parallel design with quadruple masking to assign treatments by chance. Treatments are given alongside lifestyle changes involving diet and exercise. During the trial, participants will be monitored over 92 weeks with regular assessments including body weight, waist circumference, blood pressure, blood sugar markers, cholesterol levels, and quality of life questionnaires. Safety is evaluated by tracking any adverse events. The primary measurement is the relative change in body weight from week 40 to week 92. The study is sponsored by Novo Nordisk AS and runs until mid-2028.

This research aims to find out if NNC0487-0111 is safe and effective for adults with excess body weight. The study compares this medicine to a placebo in people who have a history of unsuccessful attempts to lose weight through diet. It is a phase 3 clinical trial that evaluates treatment for obesity, focusing on weight loss and related health measures. Participants receive weekly injections under the skin with either NNC0487-0111 at one of four dose levels or a placebo. These injections are given using pre-filled pen-injectors to the thigh, abdomen, or upper arm. All participants follow a reduced-calorie diet and increase physical activity during the study. The trial lasts up to 136 weeks, with treatment and follow-up periods designed to assess long-term effects. Throughout the study, participants attend regular visits where researchers measure changes in body weight, waist circumference, blood pressure, blood sugar levels, cholesterol, and quality of life scores. Safety is monitored by tracking any adverse events during and after treatment. The main outcome is the relative change in body weight from the start of the study to week 84, with continued observation up to week 136. Participants remain under medical supervision throughout the trial.

Researchers are studying hypergranulation HG, a common issue that slows wound healing. The study aims to test a new Hypergranulation Tool designed to help healthcare professionals assess the severity of HG in wounds. This observational study will include 80 to 100 adults and children with HG in venous leg ulcers or complex surgical wounds. The goal is to validate this tools use in clinical practice and inform future treatment studies. Participants will attend 2 to 4 clinic visits where nurses will assess wounds using the Hypergranulation Tool, which grades HG based on five different parameters. Additionally, a device will take 2D wound images to create 3D models for detailed analysis of HG volume and coverage. Patient-reported outcome forms and interviews will also be collected to understand patient experiences. Throughout the study, researchers will compare the Hypergranulation Tool assessments with 3D image analysis and patient feedback to determine how well the tool performs. Safety will be monitored by tracking any adverse events related to the study procedures. The study will last until August 2026, with all assessments aimed at improving HG evaluation in clinical settings.